Abstract 1675P
Background
Adjuvant hormonal therapy (AHT) is integral to breast cancer management but often severely impacts the quality of life (QoL), especially concerning sexual functioning and psychological well-being. This study evaluates the effects of AHT on the sexual and global QoL of young breast cancer survivors.
Methods
This cross-sectional study was conducted at two cancer centers within Cairo, Egypt, involving 644 young breast cancer patients. The European Organization for Research and Treatment of Cancer EORTC QLQ - BR45 questionnaire was employed to assess the impact of AHT on sexual and global QoL. Data analysis encompassed demographic factors, treatment regimens, duration of therapy, functional and symptomatic scales of the questionnaire.
Results
The participants' median age was 41 years (range: 25-45), the primary AHT consisted of Tamoxifen + LHRH analogues (55.4%). there was a notable decrease in sexual enjoyment, with 50.7% of participants reporting no sexual activity in the past month. Among those who were sexually active, only 7.1% reported high enjoyment post-treatment compared to 31.5% pre-treatment. Additionally, 48.1% of patients experienced a complete lack of sexual desire post-treatment, while 38% expressed a significant need for psychological support. Analysis of the EORTC QLQ - BR45 questionnaire revealed Sexual Enjoyment Score: 52.9, Body image score 59.3, and Endocrine side effect score 49.4.
Conclusions
The findings reveal a profound impact of AHT on both the sexual and overall QoL among young breast cancer patients. The significant decline in sexual enjoyment and desire, coupled with a substantial need for psychological support, underscores the necessity for integrated care strategies that address the comprehensive health challenges faced by young breast cancer survivors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1646P - A multicohort phase II trial of androgen deprivation therapy (ADT), docetaxel (DOCE) and nivolumab (NIVO) in patients (pts) with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) enriched for inflamed tumours and DNA damage repair (DDR) alterations: Cohort 3 results
Presenter: Xiao Wei
Session: Poster session 11
1647P - Clinical validity of plasma DNA testing to identify BRCA-mutated (BRCA+) patients in the MAGNITUDE study
Presenter: Gerhardt Attard
Session: Poster session 11
1649P - Impact of concomitant medications on safety in patients with high-volume metastatic hormone-sensitive prostate cancer (mHSPC) receiving rezvilutamide (Rez) plus androgen-deprivation therapy (ADT): A post-hoc analysis of the randomized phase III CHART trial
Presenter: Dingwei Ye
Session: Poster session 11
1650P - Fuzuloparib plus abiraterone acetate and prednisone (AA-P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A phase I study
Presenter: Tao Dai
Session: Poster session 11
1651P - Characteristics, tolerance and effectiveness of patients aged more or less than 75 years treated with [177Lu]Lu-PSMA-617 as part of France’s early access program
Presenter: David Tonnelet
Session: Poster session 11
1652P - SAABR: Single arm phase II study of androgen receptor pathway inhibitor (ARPI) + atezolizumab + GnRH analog (ADT) and stereotactic body radiotherapy (SBRT) to the prostate in men with de novo hormone-sensitive metastatic prostate cancer (mHSPC)
Presenter: Dana Rathkopf
Session: Poster session 11
1653P - Molecular and immunologic correlates of high PSMA/FOLH1 mRNA expression in prostate cancer (PC)
Presenter: Rana McKay
Session: Poster session 11
1654P - TAMARACK: Randomized Phase II trial of the B7-H3 targeting antibody drug conjugate (ADC) vobramitamab duocarmazine (vobra duo) in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Johann de Bono
Session: Poster session 11
1655P - Association of location of BRCA1/2 pathogenic variants with benefit from PARP-inhibitors in metastatic castration-resistant prostate cancers: Results from the PROGRESS study
Presenter: Lorena Incorvaia
Session: Poster session 11